Instrument Inactif

Communiqués ProNAi Therapeutics Inc Nasdaq

Actions

US74346L1017

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

SIERRA ONCOLOGY, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	01/07/22	AQ
GSK completes acquisition of Sierra Oncology	01/07/22	AQ
SIERRA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	29/06/22	AQ
SIERRA ONCOLOGY, INC. : Other Events (form 8-K)	22/06/22	AQ
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	17/06/22	BU
SIERRA ONCOLOGY, INC. : Other Events (form 8-K)	01/06/22	AQ
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting	26/05/22	BU
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting	12/05/22	BU
Sierra Oncology, Inc: Q1 Earnings Snapshot	06/05/22	AQ
SIERRA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	06/05/22	AQ
Sierra Oncology Reports First Quarter 2022 Results	06/05/22	BU
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/05/22	BU
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA	05/05/22	BU
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA	26/04/22	BU
Sierra Oncology : GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn - Form 8-K	13/04/22	PU
SIERRA ONCOLOGY, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	13/04/22	AQ
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn	13/04/22	BU
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	07/04/22	BU
SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23/03/22	AQ
Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference	11/03/22	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ProNAi Therapeutics Inc Nasdaq

Actions

US74346L1017

Communiqués

Filtres